| Document |
Document Title |
|
WO/2023/051848A1 |
The present application provides an anti-tumor recombinant collagen, and a preparation method and use therefor. The amino acid sequence of the recombinant collagen is shown as SEQ ID NO. 1. The present application also provides an anti-o...
|
|
WO/2023/054594A1 |
The present invention addresses the problem of efficiently producing a specific peptide from a whey protein-containing ingredient. In particular, the present invention addresses the problem of providing: a flavorsome ingredient containin...
|
|
WO/2023/053132A1 |
The present invention relates to process of flocculation to purify recombinant proteins from a crude fermentation broth of Insulin and Insulin analogues or derivatives at a manufacturing scale in the presence of urea and Triton-X-100 at ...
|
|
WO/2023/052627A1 |
The present invention relates to improved industrial scale processes for removing metal cations, such as copper, from blood plasma derived albumin products and pharmaceutical compositions derived therefrom. The albumin sample is contacte...
|
|
WO/2023/051885A1 |
An apparatus for refining proteins or other biomolecules in biological compositions, such as for separation of proteins from milk, whey, blood plasma, fermentation broth, or similar.
|
|
WO/2023/056414A1 |
The present disclosure provides methods, systems, and/or kits for analyzing a polypeptide. The method and systems may comprise a native protein coupled to a support, wherein the native protein comprises one or more internal amino acids a...
|
|
WO/2023/052556A1 |
The present invention relates to methods of viral inactivation with a mixture of solvent and detergent. In particular, the present invention is directed to a method for preparing a virus- inactivated polypeptide solution wherein a polype...
|
|
WO/2023/055879A1 |
Provided herein are methods of separating molecular species of a guanine-rich oligonucleotide from a mixture of molecular species, wherein at least one molecular species of the mixture is a quadruplex formed from the guanine-rich oligonu...
|
|
WO/2023/050121A1 |
Disclosed in the present invention are biodegradable glass based on an amino acid, a peptide and a derivative, and a preparation method therefor and an application thereof. A main raw material of the glass is one of or a combination of a...
|
|
WO/2023/054285A1 |
The present disclosure relates to: an α-ray emitting antibody-drug conjugate; a method for producing same; a use thereof; a pharmaceutical composition comprising said α-ray emitting antibody-drug conjugate; and a test, diagnosis, and t...
|
|
WO/2023/053031A1 |
The present invention is directed to the use of anion exchange chromatography to produce a CTLA4-Ig fusion protein with improve glycan.
|
|
WO/2023/053030A1 |
The present invention relates to purification process of pharmacologically active IgG1 containing protein comprising at least affinity chromatography followed by mixed-mode chromatography. The present invention providescytotoxic T-lympho...
|
|
WO/2023/051801A1 |
Polyethylene glycol derivative modified interleukin-12 (IL-12), a preparation method therefor and an application thereof. The polyethylene glycol derivative modified IL-12 is obtained by performing a modification reaction on a polyethyle...
|
|
WO/2023/055045A1 |
The present invention relates to: a polypeptide comprising a self-assembling domain; a fusion protein comprising the polypeptide; a nucleic acid molecule encoding same; or a composition comprising the polypeptide, fusion protein or nucle...
|
|
WO/2023/055043A1 |
The present invention relates to a method for the purification of collagen from the extracellular matrix, the method comprising the steps of: (a) destaining the extracellular matrix; (b) eliminating non-collagenous proteins from the dest...
|
|
WO/2023/053032A1 |
The present invention relates to purification process of pharmacologically active cytotoxic T lymphocyte-associated 4-immunoglobulin (CTLA4-lg) fusion protein by using three column chromatography steps that provides purified form of the ...
|
|
WO/2023/049687A1 |
This invention provides a method of controlling the level of dissolved oxygen in a solution comprising a recombinant protein in a storage container.
|
|
WO/2023/048262A1 |
Provided are: a method for producing a ligated peptide, characterized by forming an amide bond between the C-terminal of a donor peptide substrate (donor substrate) and the N-terminal of an acceptor peptide substrate (acceptor substrate)...
|
|
WO/2023/047368A1 |
The present invention relates to an improved method of quantification and/or estimation of purity of antibody or fusion protein from a protein mixture containing impurity by providing long term sample stability. The invention provides a ...
|
|
WO/2023/049479A1 |
Processes for producing oligo-chromopeptides from phycocyanin are disclosed. Additionally, compositions comprising oligo-chromopeptides and combination of oligo-chromopeptides with at least one of the compounds namely, nicotinamide ribos...
|
|
WO/2023/046886A1 |
The present disclosure relates to a class of engineered polypeptides having a binding affinity for the Fc region of immunoglobulins while exhibiting a significantly reduced binding affinity to the VH3 region of immunoglobulins. The prese...
|
|
WO/2023/048291A1 |
The present invention provides tRNA produced by modifying the tRNA for tryptophan from Mycoplasma pneumoniae. The anticodon of the tRNA is UUA, and the tRNA pairs with the UAA codon. The present invention also provides a use for the tRNA.
|
|
WO/2023/049748A1 |
This disclosure relates to methods and compositions for labeling, isolating, detecting, measuring, and purifying tertiary amines. In certain embodiments, the tertiary amine has a dimethyl amine such as in the case of dimethyl lysine, and...
|
|
WO/2023/049177A1 |
The present description provides methods, assays and reagents for linearly expanding a peptide. The methods and/or linear expanded peptide described herein have several uses such as, but not limited to, peptide (protein) sequencing, high...
|
|
WO/2023/044423A1 |
Provided in this disclosure are pharmaceutical formulations and kits comprising antimicrobial peptides with a basic pH, wherein the antimicrobial peptide is in combination with sodium bicarbonate. Further provided herein are methods of t...
|
|
WO/2023/040177A1 |
A segmented extraction device for a nutrient solution used in giant salamander protein production, which belongs to the technical field of biological extraction, and comprises a casing assembly (1), and further comprises a liquid supply ...
|
|
WO/2022/020569A9 |
The present invention provides methods, assays and kits for assessment of patients positive for SARS-CoV-2 infection and methods of diagnosis and treatment of COVID-19 disease and for assessment and evaluation of individuals prior to vac...
|
|
WO/2023/040792A1 |
A preparation method for erythropoietin, specifically, a protein separation method. The protein is in contact with two or more cation exchangers, wherein one of the cation exchangers is a fine cation exchanger.
|
|
WO/2023/039833A1 |
A use of collagen particles in the preparation of a pharmaceutical product which promotes hair follicle formation or angiogenesis of an individual. The particle size of the collagen particles are about 10 to 200 micrometers and are admin...
|
|
WO/2023/040083A1 |
A preparation method for and a product of sea bream collagen peptide. The sea bream collagen peptide is prepared by using sea bream fish bones as raw material, and carrying out raw material pretreatment, decalcification and degreasing, e...
|
|
WO/2022/085606A9 |
Provided is a method for deactivating or removing viruses in a protein solution, the method including a step in which radiation treatment and virus removal membrane treatment or SD treatment are integrated and the conditions of these tre...
|
|
WO/2023/044004A1 |
A process for deprotecting an amino acid during solid phase peptide synthesis includes removing a protecting group of a protected amino acid with a deprotecting agent in a reaction vessel, during which at least a portion of the deprotect...
|
|
WO/2023/043911A1 |
The present invention relates to peptide manipulation systems and methods for modifying the folding trajectory and facilitating the folding of a polypeptide chain into native, non-native, or artificial conformations. The invention compri...
|
|
WO/2023/035720A1 |
The present application relates to a method for preparing a pegylated collagen-like protein and the use thereof, which belong to the field of biotechnology. Provided in the present application is a method for preparing a pegylated collag...
|
|
WO/2023/039062A1 |
Peptide nucleic acid (PNA) oligomers are polymeric nucleic acid mimics that can bind to nucleic acids with high affinity and sequence specificity. In order to design PNA oligomers with customizable binding properties, it would be helpful...
|
|
WO/2023/035718A1 |
Disclosed are an echinocandin drug impurity, a preparation and purification method therefor and an application thereof. The echinocandin drug impurity has a structure represented by formula I: the echinocandin drug impurity is prepared b...
|
|
WO/2023/039068A1 |
The present disclosure provides intermediates for the synthesis of peptide nucleic acid (PNA) backbones and monomers, such as cyclic intermediates, and methods of making the same.
|
|
WO/2023/035719A1 |
Provided is a pegylated collagen-like protein. The pegylated collagen-like protein contains a collagen-like protein, and PEG-40k and PEG-20k modified on the collagen-like protein; the modification of PEG-40k and PEG-20k can significantly...
|
|
WO/2023/030277A1 |
Provided is a method for fully liquid-phase synthesis of a GRnH nonapeptide amide analog, which belongs to the technical field of medicine synthesis. The method comprises respectively synthesizing a "Trp-Ser-Tyr" fragment, an "R-Leu" fra...
|
|
WO/2023/028654A1 |
The disclosure provides methods of removing aggregate from a composition comprising a protein, an aggregate of the protein and a liquid carrier. The method involves subjecting the composition to one or more filtering steps comprising pas...
|
|
WO/2023/029161A1 |
A natural collagen material, a preparation method and an application of the natural collagen material, and a subdermal filler, belonging to the field of biomedical materials. The natural collagen material has a significantly increased co...
|
|
WO/2023/030995A1 |
The present relates to a polypeptide that binds to an immunoglobulin or a fragment thereof. More specifically, it relates to a kappa light-chain binding polypeptide with high binding affinity and improved alkali stability. The one kappa ...
|
|
WO/2023/031462A1 |
The present invention relates to a method for cell-free production of unspecific peroxygenases, preferably from fungi and/or genetically modified variants thereof, using eukaryotic cell extracts, preferably from fungi, in particular fila...
|
|
WO/2023/030064A1 |
The present application relates to a method for improving the quality of an antibody-drug conjugate product. The method comprises: conjugating a drug to be conjugated to an antibody to obtain an antibody-drug conjugate; and purifying the...
|
|
WO/2023/033016A1 |
Provided are: a guanidyl-protected arginine compound which, when used in a liquid-phase peptide synthesis reaction, renders satisfactory liquid-liquid separation possible; and a peptide synthesis method in which the guanidyl-protected ar...
|
|
WO/2023/033015A1 |
Provided is a method for producing a Fmoc-protected amino group-containing compound, wherein a raw material amino group-containing compound is not wasted, by-production of Fmoc-β-Ala-OH is suppressed, and the purification of a target su...
|
|
WO/2023/032996A1 |
A compound which has at least two phosphor parts and a structure represented by general formula (I), and a labeled biomaterial. In the formula, X1 to X3 represent -O-, -S-, >NR1 or >CR2R3. R1 to R3 represent a hydrogen atom or a substi...
|
|
WO/2023/030278A1 |
Provided is a full-liquid-phase synthesis method for a reelin drug, belonging to the technical field of medicine synthesis. A liquid-phase method is used to synthesize "Trp-Ser-Tyr" fragments, "R5-Leu" fragments, "PYR-His" fragments, and...
|
|
WO/2023/031965A1 |
The current invention discloses a method for obtaining a purified antibody composition. The method discloses the use of various chromatography steps in a particular order to obtain a purified composition of a therapeutic monoclonal antib...
|
|
WO/2023/031445A2 |
The present invention relates to novel, improved aminoacyl-tRNA synthetase variants, which are useful for genetic code expansion. The present invention also relates to corresponding coding sequences and eukaryotic cell lines comprising s...
|
